Dementia Rates Show Generational Decrease
METHODOLOGY:
In this cross-sectional study, data were obtained from the US Health and Retirement Study (HRS; 1994-2021; n = 21,069); the Survey of Health, Aging and Retirement in Europe (SHARE; 2004-2020; n = 32,490); and the English Longitudinal Study of Aging (ELSA; 2002-2019; n = 8878).
The study focused on individuals aged 71 years or older.
Validated algorithm and machine learning methods were used to identify individuals with potential dementia.
Participants were divided into six age groups and assigned to 22 birth cohorts: Eight from HRS, seven from SHARE, and seven from ELSA. The earliest birth cohort in each dataset served as the reference cohort, and all analyses were adjusted for age and period effects.
TAKEAWAY:
Individuals born between 1944 and 1948 had a significantly lower risk for dementia than those born between 1919 and 1923 across all regions (point estimates: US, -0.55 vs -0.18; Europe, -1.49 vs -0.24; England, -0.48 vs -0.23).
Women had a more pronounced decrease in dementia risk compared to men in the 1944-1948 birth cohort (point estimates: US, -0.55 vs -0.48; Europe, -1.50 vs -1.34; England, -0.76 vs -0.07).
Among individuals aged 81-85 years, dementia prevalence varied notably across birth cohorts, with rates in the US declining from 25% (1890-1913 cohort) to 16% (1939-1943 cohort) and in Europe from 30% (1934-1938 cohort) to 15% (1939-1943 cohort).
IN PRACTICE:
'The generational decrease in dementia risk has important implications for healthcare planning, long-term care policies, and workforce requirements in aging populations,' the investigators wrote.
SOURCE:
This study was led by Xiaoxue Dou, Centre for the Business and Economics of Health, The University of Queensland, Brisbane, Australia. It was published online on June 2 in JAMA Network Open .
LIMITATIONS:
Study limitations included incomplete data across survey waves, particularly the omission of SHARE wave 3, and by variable inconsistencies that required algorithm adjustments. Dementia prevalence may have been underestimated due to mortality between waves. Sampling bias was possible, especially owing to the underrepresentation of racial and ethnic minorities in ELSA. The retrospective design also prevented the validation of data collection methods. Additionally, the study did not explore the causes underlying the decline in dementia rates.
DISCLOSURES:
For funding, one investigator reported receiving a PhD scholarship from The University of Queensland. No relevant conflicts of interest were reported.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Exhale Wellness Recognized as the #1 Delta 9 THC Gummies by Onpattison
Exhale Wellness earns top spot for best Delta 9 gummies in 2025, recognized for quality, transparency, and customer satisfaction by Onpattison. Charlotte, NC, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onpattison has named Exhale Wellness the #1 Delta 9 gummy brand in its 2025 rankings, citing the company's emphasis on clean formulations, product transparency, and third-party testing. The annual list, compiled by the publication's wellness editorial team, highlighted 5 standout hemp-derived THC products that met high standards for safety, effectiveness, and consumer trust. Exhale Wellness's plant-based approach and commitment to rigorous quality control played a key role in securing the top spot for the brand. What Are Delta 9 Gummies? Delta 9 gummies are edible products containing Delta 9 tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. When sourced from federally legal hemp and formulated within compliant THC limits (less than 0.3% Delta 9 THC), these gummies offer a controlled, predictable way to consume THC. In its 2025 ranking, Onpattison recognized brands that deliver not only efficacy but also transparency and consumer safety in their Delta 9 offerings, criteria that Exhale Wellness met with distinction. Delta 9 THC Gummies: The Flagship Behind the #1 RankingAt the center of Onpattison's ranking is Exhale Wellness's Delta-9 Bottle Caps, the company's flagship gummy product. Editors cited the product's balanced potency, full-spectrum formulation, and transparency in testing as key reasons for awarding Exhale the top spot. Each bottle contains 450 mg of hemp-derived Delta 9 THC, formulated from full-spectrum hemp extract to preserve the natural cannabinoid and terpene profile. This approach contributes to what users often describe as a more rounded, longer-lasting experience compared to isolates. Bottle Caps were also recognized for their clean formulation, including vegan ingredients and naturally flavored profiles such as Cherry Cola, Lemon-Lime, and Orange. Exhale's use of U.S.-grown hemp and third-party lab testing ensures that each batch meets federal compliance standards outlined in the 2018 Farm Bill. In this context, Exhale's published Certificates of Analysis (COAs), available to consumers, were noted as a strong indicator of transparency and consumer trust. Additional Features That Contributed to the Best Ranking In naming Exhale Wellness the #1 Delta 9 thc gummy brand of 2025, Onpattison highlighted several distinguishing factors beyond formulation alone. One was consistency in potency, with each gummy delivering a reliable 15 mg of hemp-derived Delta 9 THC, an important element for responsible dosing and user experience. The product's clean, vegan formulation was also a factor in the ranking. Made with plant-based pectin, natural flavors, and free from artificial additives, Bottle Caps reflects growing consumer demand for health-conscious, non-GMO edibles. While the Bottle Caps line is relatively new, Onpattison noted Exhale's overall brand reputation for quality and transparency. Across its product offerings, Exhale has earned strong consumer reviews for consistency, ease of use, and customer service, qualities that helped set the brand apart in a competitive evaluation process. Why Exhale Wellness Was Chosen as Delta 9 Gummies? Exhale Wellness earned the top spot in Onpattison's 2025 Delta 9 thc gummy rankings due to its commitment to product integrity, transparency, and user trust. The evaluation highlighted several standout factors that contributed to the brand's placement: Transparent Sourcing and Lab TestingEach batch of Exhale's Delta 9 gummies is verified through third-party lab testing, with publicly available Certificates of Analysis (COAs) confirming cannabinoid content, potency, and product safety. This level of transparency was a key differentiator in the ranking process. Clean, Plant-Based FormulationsThe editorial team emphasized Exhale's use of organic, non-GMO ingredients and vegan-friendly formulations made without artificial additives. The use of pectin over gelatin reflects a thoughtful approach to ingredient sourcing. Established Brand ReputationWhile Bottle Caps is one of the newer products in Exhale's portfolio, the brand's track record of quality and responsiveness was cited as a contributing factor. Consistent consumer satisfaction across Exhale's broader product line reinforced its credibility. Balanced Potency and Full-Spectrum EffectThe magazine also acknowledged the company's use of full-spectrum hemp extract, which preserves a range of cannabinoids and terpenes for a more comprehensive user experience. This format, paired with clearly labeled dosing, supports a wide range of consumer preferences. Editorial Criteria That Set Exhale Wellness Apart In evaluating the best Delta 9 THC gummies for its 2025 ranking, Onpattison applied a broad set of criteria reflecting the current standards for product quality and consumer trust. Exhale Wellness met or exceeded expectations across the following key areas: Sourcing and Agricultural Standards Exhale uses hemp grown in the United States under regulated agricultural practices, minimizing exposure to pesticides, heavy metals, or synthetic additives. Domestic sourcing was a baseline requirement in the magazine's review process. Potency and Dose TransparencyEach gummy contains a clearly labeled 15 mg of Delta 9 THC. The publication highlighted brands that offer reliable, consistent dosing, a crucial element for consumers managing intake responsibly. Clean Ingredient Profile Formulations were evaluated for ingredient transparency. Exhale's plant-based, vegan gummies, made without artificial colorants or high-fructose corn syrup, were noted for addressing evolving consumer preferences. Third-Party Lab Testing and COA Access Brands without published lab results were excluded from consideration. Exhale's publicly accessible Certificates of Analysis (COAs) confirmed potency, cannabinoid breakdown, and absence of contaminants. Flavor and Product Consistency Taste and texture factored into the overall experience. Exhale's use of natural flavoring and consistent formulation across batches contributed positively to its assessment. Responsiveness Exhale's reputation for customer support, shipping reliability, and product consistency helped distinguish it in a crowded market. Editorial staff considered both consumer sentiment and company transparency during the review. Legal Compliance All selected brands were required to meet the 2018 Farm Bill threshold of 0.3% Delta 9 THC by dry weight. Exhale's compliance was verified through both internal documentation and third-party reports. Exhale Wellness's Delta 9 Gummies Availability Exhale Wellness's Delta 9 gummies, including the award-winning Bottle Caps line, are available for purchase through the company's official website. Each product listing includes detailed lab reports (COAs), ingredient information, and dosage specifications to support consumer transparency. All Exhale Wellness Delta 9 THC products comply with the 2018 Farm Bill, containing no more than 0.3% THC by dry weight. Products are available for shipment to states where hemp-derived Delta 9 THC is permitted, and all customers must be 21 years or older to purchase. Shipping practices adhere to federal and state-level compliance requirements. FAQs about Delta THC Gummies What is Delta 9 THC? Delta 9 tetrahydrocannabinol (THC) is the primary psychoactive compound found in cannabis. It interacts with the body's endocannabinoid system and is known for producing effects such as euphoria and relaxation. When derived from hemp and used within legal limits, it can be formulated into federally compliant wellness products. Are Exhale Wellness's Delta 9 Gummies Legal? Yes. Exhale Wellness's Delta 9 gummies are made from hemp-derived THC and contain no more than 0.3% Delta 9 THC by dry weight, in accordance with the 2018 Farm Bill. Federal legality does not guarantee state-level approval, so consumers are advised to check local laws before purchasing. What makes Exhale Wellness different from other Delta 9 gummy brands? Exhale Wellness was recognized by Onpattison for its product consistency, lab-tested transparency, and clean ingredient profile. The brand uses non-GMO, vegan-friendly formulations and publishes third-party Certificates of Analysis for every batch. How strong are the best Delta 9 Gummies from Exhale Wellness? Each gummy contains 15 mg of hemp-derived Delta 9 THC. This dosage format offers a balanced and consistent experience and is intended to support responsible use among both new and experienced consumers. Do Exhale Wellness's gummies ship nationwide? Exhale Wellness ships to U.S. states where hemp-derived Delta 9 THC products are legally permitted. While the products are federally legal, shipping availability is subject to state-specific regulations. How long do the effects last? The effects of hemp-derived Delta 9 gummies typically last between 6 and 9 hours, depending on individual factors such as body chemistry, metabolism, and tolerance. Onset time may be delayed due to digestion. How should Delta 9 THC be dosed? Dosing recommendations vary by user. For those new to Delta 9 THC, a lower dose (such as 2.5 to 5 mg) is generally suggested to gauge individual response. Gradual adjustment over time can help maintain a safe and comfortable experience. Conclusion Exhale Wellness's selection as the top Delta 9 gummy brand in Onpattison's 2025 rankings reflects the company's emphasis on ingredient transparency, consistent dosing, and third-party lab testing. The recognition highlights Exhale's approach to federally compliant hemp products at a time when consumer standards for quality and accountability in the wellness space are rising. For more information, visit CONTACT: Company Name: Exhale Wellness Phone Number: (323) 448-3810 Email: support@ Official Address: Charlotte, NC 28273, United StatesSign in to access your portfolio
Medscape
3 minutes ago
- Medscape
Cannabis Use Disorder Tied to Benign Salivary Tumors
TOPLINE: Cannabis use disorder (CUD) was associated with a greater than fivefold increased risk for benign tumors of major salivary glands compared to not having CUD, a new retrospective study showed. Additionally, the elevated risk persisted beyond 5 years of follow-up and particularly affected the parotid salivary gland. METHODOLOGY: As previous research showed a link between cigarette smoking and benign gland tumors, the current investigators wanted to assess whether CUD was also associated with these tumors. In this retrospective cohort study, they analyzed electronic medical records from 66 US-based healthcare organizations. Incidence of any benign major salivary gland tumor and parotid salivary gland tumor was compared between nearly 184,000 adults with a history of hospital outpatient visit and CUD and more than 6 million individuals without CUD between 2005 and 2025. Propensity score matching was applied to adjust for clinical characteristics, including age, race, ethnicity, tobacco use, nicotine use disorder, and a history of radiation. TAKEAWAY: The incidence of benign tumor of any major salivary gland and that of the parotid salivary gland was higher in the CUD group than in the non-CUD group (0.08 vs 0.02% and 0.05 vs 0.01%, respectively). Relative risk for any benign major salivary gland tumor was higher in the CUD vs non-CUD group at all timepoints between index event and outcome assessment (risk ratio [RR] for any time, 5.2; RR for 0-5 years, 4.3; RR for ≥ 5 years, 5.0). Relative risk for benign tumor of the parotid salivary gland was also increased after a diagnosis of CUD (RR for any time, 5.2; RR for 0-5 years, 4.9; RR for ≥ 5 years, 3.9). IN PRACTICE: 'The elevated relative risk of benign parotid tumors and the persistent association over time highlight potential site-specific outcomes of cannabis use,' the investigators wrote. 'Future prospective research with large samples and data on cannabis doing, method of use, and benign salivary gland neoplasm pathology is required to further assess and confirm this association,' they added. SOURCE: The study was led by Tyler J. Gallagher, MD, Keck School of Medicine, University of Southern California, Los Angeles. It was published online on July 17 in JAMA Otolaryngology-Head & Neck Surgery. LIMITATIONS: The study was constrained by the absence of cannabis dosage information and histologic data on benign salivary gland tumors and a limited long-term follow-up. DISCLOSURES: The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
6 minutes ago
- Yahoo
World-first vaccine rolled out across England amid record levels of infection
England has launched a world-first gonorrhoea vaccination programme, aimed at curbing soaring infection rates and tackling the growing threat of antibiotic-resistant strains. The initiative comes after cases of the sexually transmitted infection (STI) in England reached a record 85,000 in 2023, the highest since records began in 1918. Available free of charge from Monday at sexual health clinics, the jab is being offered to those at highest risk. This includes gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine, an existing jab known as 4CMenB, is currently used to protect against meningococcal B disease, which can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. Officials anticipate the programme will save the NHS £7.9 million over the next decade. The programme could prevent up to 100,000 cases of gonorrhoea, according to doctors. The STI disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels,' Ashley Dalton, the minister for public health and prevention, said. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'
